Ezetimibe/Simvastatin and Cyclosporine Interaction
Drug interaction information between Ezetimibe/Simvastatin and Cyclosporine.
Ezetimibe/Simvastatin and Cyclosporine have a documented major interaction in FDA labeling.
FDA drug labeling documents a major-severity interaction between Ezetimibe/Simvastatin and Cyclosporine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Cyclosporine causes a large increase in simvastatin levels in your blood, which can lead to a dangerous condition where muscle tissue breaks down.
What To Do
You should not take these two medications together at the same time.
FDA Label Information
Cyclosporine, Danazol, or Gemfibrozil Clinical Impact: The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine, danazol, or gemfibrozil with VYTORIN. Intervention: Concomitant use of cyclosporine, danazol, or gemfibrozil with VYTORIN is contraindicated [see Contraindications (4) ] .
Ezetimibe/Simvastatin Also Interacts With
- Amlodipine major
- Diltiazem major
- Verapamil major
- Amiodarone major
- Dronedarone major
Cyclosporine Also Interacts With
- Clarithromycin major
- Ezetimibe major
- Pitavastatin major
- Simvastatin major
- Aliskiren moderate
Frequently Asked Questions
Can I take Ezetimibe/Simvastatin and Cyclosporine together?
This is a major interaction. You should not take these two medications together at the same time.
How serious is the interaction between Ezetimibe/Simvastatin and Cyclosporine?
This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.
Why do Ezetimibe/Simvastatin and Cyclosporine interact?
Cyclosporine causes a large increase in simvastatin levels in your blood, which can lead to a dangerous condition where muscle tissue breaks down.
Understanding the Ezetimibe/Simvastatin and Cyclosporine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Ezetimibe/Simvastatin belongs to the Cholesterol Absorption Inhibitor / Statin Combination class and Cyclosporine belongs to the Calcineurin Inhibitor (Immunosuppressant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cyclosporine causes a large increase in simvastatin levels in your blood, which can lead to a dangerous condition where muscle tissue breaks down. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Ezetimibe/Simvastatin has 23 total documented interactions on file in this dataset, and Cyclosporine has 89. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should not take these two medications together at the same time. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Ezetimibe/Simvastatin or Cyclosporine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.